MarginsXMarginsX
Home › Markets › Health Care › OBX

Obsidian Therapeutics Inc. (OBX)

OBX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$12.36
-1.59% on the day
Market cap
$763.5M
Small cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$100.6M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerOBX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0002130606
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$0
Net income-$100.6M
Operating income-$105.7M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$40.4M
Total assets$88.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
Cash-flow positive
$66.5M cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$66.5M cash; operating cash flow $0 a quarter.Report 2026-06-30
Shares outstanding61,774,046 (2026-11-09).Cover page 2026-11-09
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months8-K 4.01 2026-08-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$50.7MNot filed$66.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed$0$0$0No debt tagsNeeds four quarters10-Q 2026-08-14
Q3 2026
2026-03-31
Not filed-$19.6MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-09-30
$0-$28.5MNot filed$37.4MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-06-30
Not filed-$26.9MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12
Q3 2026
2025-03-31
Not filed-$25.0MNot filedNot filedNo debt tagsNeeds four quarters10-Q 2026-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-11-12
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 44 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-9.4%
1 month+4.8%
3 months-33.6%
Year to dateNot enough price history
1 yearNot enough price history
From 52-week high-64.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ARDXArdelyx Inc.$3.07-0.65%$771.7M
LXRXLexicon Pharmaceuticals Inc.$1.75-2.23%$779.2M
ORICOric Pharmaceuticals Inc.$7.52-4.33%$779.5M
IVAInventiva S.A. American Depository Shares$3.32-9.78%$784.5M
COLLCollegium Pharmaceutical Inc.$25.43+0.43%$790.2M
IRWDIronwood Pharmaceuticals Inc.$4.85+0.41%$802.9M
SGMTSagimet Biosciences Inc. Series A$10.13-0.88%$723.0M
SNDXSyndax Pharmaceuticals Inc.$9.13-3.39%$821.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier